Dermatology
Latest News
Apremilast may have some cardiometabolic benefits in patients with psoriasis
The trial does help answer the question of whether apremilast can induce weight loss ... something that earlier trials suggested.
From the Journals
Psoriasis, psoriatic arthritis insurance coverage remains restrictive
A database review showed restrictive coverage of specialty medications for psoriatic disease beyond the label indications.
Latest News
When is an allergic reaction to raw plant food due to tree pollen?
Allergy tests may be needed for people who report atypical or severe reactions or who also react to cooked or processed plant foods.
Latest News
Uncombable hair syndrome: One gene, variants responsible for many cases
A deficiency in the shaping and mechanical strengthening of the hair shaft occurs in the UHS phenotype, which is characterized by dry, frizzy, and...
Opinion
A White male presented with a 1-month history of recurrent, widespread, painful sores
A man presented with a 1-month history of recurrent, widespread, painful sores.
From the Journals
New science reveals the best way to take a pill
Posture determined as much as 83% of how quickly a pill disperses into the intestines.
Latest News
Brodalumab suicide risk similar to other biologics, postmarket study finds
The researchers extracted data through the end of 2021 on the number of completed suicides for brodalumab and ten other biologics approved for...
Latest News
Hope shines bright for hidradenitis suppurativa treatments
Research into HS is "an incredibly active field at this moment," said Alexa B. Kimball, MD, MPH.
Latest News
Pandemic has helped clinicians to gain better insight on pernio, expert says
“I don’t think pernio is truly necrotic,” Dr. Lindy P. Fox said. “I think it’s really inflammatory and purpuric.”
Latest News
Sustained response at 2 years reported for newly approved oral psoriasis agent
Long-term results with the JAK inhibitor for psoriasis show responses persist.
Latest News
Targeted anti-IgE therapy found safe and effective for chronic urticaria
Two phase 3 trials associated ligelizumab with efficacy comparable to omalizumab, an approved CSU therapy.